Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Medical Sciences Division today partnered with Muscular Dystrophy UK to develop the multi-million pound Oxford Neuromuscular Translational Research Centre.

The centre, which involves Professor Kevin Talbot from NDCN, aims to bring new treatments to neuromuscular disease patients more quickly and is part of an investment from MDUK of over £4.5 million into five new transformational commitments. 

Read more 

Similar stories

First participant recruited to pioneering UK trial in global effort to tackle early causes of Parkinson’s

A pioneering clinical trial for people with a sleep disorder who are at higher risk of developing Parkinson’s has recruited its first UK participant from the Discovery Cohort study at the Oxford Parkinson’s Disease Centre (OPDC)